Jason Abdou Mouabbi, MD

Assistant Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Articles

Applying ctDNA Insights to Real-World Decisions and Tumor Evolution

July 15th 2025

Panelists discuss the real-world challenges of managing patients with positive circulating tumor DNA (ctDNA) but no radiographic evidence of disease, emphasizing treatment intensification, genomic profiling for resistance mutations, dynamic monitoring, and the integration of ctDNA with imaging and biopsy to guide personalized breast cancer care.

Personalizing Posttreatment Care: Insights From DARE, LEADER , and Emerging MRD Trials

July 15th 2025

Panelists discuss ongoing studies exploring circulating tumor DNA (ctDNA) use in the adjuvant breast cancer setting to detect recurrence earlier and guide therapy, highlighting advances in assay sensitivity, the choice between tumor-informed and tumor-agnostic tests, and the challenge of turning ctDNA’s strong prognostic value into actionable, outcome-improving interventions.

Beyond Traditional Biomarkers: Prognostic Impact of ctDNA in the Posttreatment Setting

July 8th 2025

Panelists discuss how circulating tumor DNA (ctDNA) serves as a highly predictive prognostic biomarker in breast cancer, guiding personalized treatment intensification and informing important patient decisions while enhancing risk stratification and motivating proactive care despite ongoing research into its impact on long-term outcomes.

Monitoring Response in Real Time: ctDNA as a Predictive and Surrogate Marker in Early Treatment

July 8th 2025

Panelists discuss how circulating tumor DNA (ctDNA) is becoming a vital biomarker in breast cancer, with its dynamic changes guiding personalized treatment decisions, serving as a surrogate end point in trials, enabling earlier detection of progression, and offering a less-invasive monitoring tool that complements imaging—especially benefiting patients with hard-to-monitor disease or those who are frail.

Sequencing, Safety, and the Evolving Role of Oral SERDs in HR+/HER2– mBC

July 4th 2025

A panelist discusses how clinicians should exhaust all endocrine therapies plus targeted therapies before moving to chemotherapy or antibody-drug conjugates, while noting that different oral SERDs have varying adverse effect profiles that patients should be counseled about.

Oral SERDs in ER+/HER2– mBC: Current Data and Future Directions

July 4th 2025

A panelist discusses how the EMBER-3 study results cannot be directly compared to those from EMERALD because of different patient populations, with EMBER-3 having fewer heavily pretreated patients and different baseline characteristics.

Personalizing Early Breast Cancer Care: ctDNA Surveillance Insights From E-BLIS and I-SPY 2

July 1st 2025

Panelists discuss how emerging data from studies like E-BLIS and I-SPY 2 validate circulating tumor DNA (ctDNA) as a powerful prognostic tool in early breast cancer, showing it can detect recurrence months before imaging and potentially refine risk stratification beyond traditional markers, though its role in guiding treatment decisions remains under active investigation.

Optimizing MRD Monitoring: Integrating Clinical and Genomic Insights

July 1st 2025

Panelists discuss how circulating tumor DNA (ctDNA) monitoring provides a valuable lead time for detecting recurrence in early-stage breast cancer—especially hormone receptor–positive cases—yet requires careful patient counseling and integration with traditional prognostic tools, as its use for guiding treatment decisions remains nuanced and dependent on evolving clinical evidence.

Dr Mouabbi on Developing Consensus Around Treatment De-Escalation in HER2+ Breast Cancer Following pCR

June 27th 2025

Jason A. Mouabbi, MD, discusses the importance of achieving consensus for integrating CompassHER2-pCR data into early-stage HER2+ breast cancer management.

Combination Strategies in HR+/HER2– mBC: Insights From the ELEVATE Trial

June 27th 2025

A panelist discusses how combination studies like ELEVATE are exploring elacestrant with other targeted therapies, showing promising results with ribociclib and everolimus combinations that are well-tolerated and efficacious.

Oral SERDs in Practice: Real-World Insights on Elacestrant for HR+/HER–- mBC

June 27th 2025

A panelist discusses how real-world studies of elacestrant showed even better outcomes than clinical trials, with progression-free survival approaching 9 months, demonstrating the drug’s effectiveness in broader patient populations.

Molecular Residual Disease Detection and Surveillance Protocols in Practice

June 24th 2025

Panelists discuss how circulating tumor DNA (ctDNA) testing for molecular residual disease (MRD) offers a sensitive tool for detecting early breast cancer recurrence before clinical symptoms appear while emphasizing the importance of shared decision-making, patient education, and clinical trial referral in the absence of standardized guidelines for managing ctDNA-positive results.

Evolving Standard-of-Care Treatment Strategies Across Breast Cancer Subtypes

June 24th 2025

Panelists discuss how current breast cancer surveillance remains largely symptom-driven and reactive, often missing early metastatic recurrence, and how circulating tumor DNA (ctDNA) testing offers a promising shift toward proactive, personalized monitoring by enabling earlier detection of molecular residual disease (MRD) and guiding timely therapeutic interventions.

Expert Insights on Patient Selection and Sequencing Strategies in HR+/HER2– mBC

June 20th 2025

A panelist discusses how elacestrant should be used as soon as ESR1 mutations emerge, emphasizing that it works equally well in visceral and bone metastases and that ESR1 mutations must be targeted before other mutations due to their resistance-driving nature.

The Role of Elacestrant in HR+/HER–- mBC: Insights From the EMERALD Trial

June 20th 2025

A panelist discusses how the landmark EMERALD study established elacestrant as an effective treatment for heavily pretreated patients with ESR1 mutations, showing 8 to 9 months median progression-free survival versus less than 2 months with standard care.

Serial ESR1 Mutation Testing in HR+/HER2– mBC: Insights From SERENA-6

June 13th 2025

A panelist discusses how the SERENA-6 study presented at ASCO 2025 showed that switching therapy early based on molecular progression (ESR1 mutation emergence) before radiological progression improved outcomes, with a 60% reduction in risk.

Integrating ESR1 Testing Into Treatment Planning for HR+/HER2- Metastatic Breast Cancer

June 13th 2025

A panelist discusses how testing for ESR1 mutations should be performed after every progression using liquid biopsies and how elacestrant is currently the only approved oral SERD that effectively targets these mutations.

Dr Mouabbi on the Rationale for Early, Serial ESR1 Mutation Testing in HR+ Breast Cancer

April 25th 2025

Jason A. Mouabbi, MD, discusses how ESR1 mutations can cause patients with HR-positive, HER2-negative breast cancer to develop endocrine resistance.

Dr Mouabbi on Challenges Diagnosing and Managing Invasive Lobular Carcinoma

August 14th 2024

Jason A. Mouabbi, MD, discusses challenges associated with diagnosing and managing invasive lobular carcinoma

Dr Mouabbi on Clinical Trials for Invasive Lobular Breast Cancer

July 23rd 2024

Jason A. Mouabbi, MD, discusses clinical trials aimed at expanding the treatment paradigm for invasive lobular breast cancer.